| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-13075SS | |||
| Azide and BSA Free | NBP2-80594 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-268SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-60531SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-202SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-556-0.025ml | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-140-0.025ml | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-91810-25ul | |||
![Western Blot: TDP-43/TARDBP Antibody (2E2-D3) [H00023435-M01] - TARDBP monoclonal antibody (M01), clone 2E2-D3 Analysis of TARDBP expression in A-431.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-2E2-D3-Western-Blot-H00023435-M01-img0025.jpg "Western Blot: TDP-43/TARDBP Antibody (2E2-D3) [H00023435-M01] - TARDBP monoclonal antibody (M01), clone 2E2-D3 Analysis of TARDBP expression in A-431.")
![Immunohistochemistry-Paraffin: TDP-43/TARDBP Antibody (2E2-D3) [H00023435-M01] - TARDBP in rat tissue samples. Image courtsey of product review by Daniel Pirici.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-2E2-D3-Immunohistochemistry-Paraffin-H00023435-M01-img0011.jpg)
![Western Blot: TDP-43/TARDBP Antibody (2E2-D3) [H00023435-M01] - PDI co-precipitates with TDP-43/TARDBP and is increased in mutant TDP-43 transgenic mouse spinal cords. Co-immunoprecipitation of wildtype and mutant Q331K TDP-43-mCherry from Neuro2a cell lysates using an anti-PDI antibody followed by TDP-43 immunoblot. Control immunoprecipitations were performed using untransfected (Untrans) or mCherry expressing cell lysates, buffer only with coprecipitating antibodies or TDP-43 Q331K cell lysates using an irrelevant, isotype-matched control antibody (IgG). Input control (2%) shows expression of mCherry-TDP43 in wildtype and Q331K cell lysates. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0081170) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-2E2-D3-Western-Blot-H00023435-M01-img0028.jpg)
![Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody (2E2-D3) [H00023435-M01] - Analysis of monoclonal antibody to TARDBP on HeLa cell. Antibody concentration 10 ug/ml.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-2E2-D3-Immunocytochemistry-Immunofluorescence-H00023435-M01-img0019.jpg)
![Immunohistochemistry-Paraffin: TDP-43/TARDBP Antibody (2E2-D3) [H00023435-M01] - TARDBP on formalin-fixed paraffin-embedded human leiomyosarcoma. [antibody concentration 3 ug/ml]](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-2E2-D3-Immunohistochemistry-Paraffin-H00023435-M01-img0013.jpg)
![Western Blot: TDP-43/TARDBP Antibody (2E2-D3) [H00023435-M01] - Analysis of TARDBP expression in transfected 293T cell line by TARDBP monoclonal antibody (M01), clone 2E2-D3.Lane 1: TARDBP transfected lysate(44.7 KDa).Lane 2: Non-transfected lysate.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-2E2-D3-Western-Blot-H00023435-M01-img0026.jpg)
![Immunohistochemistry-Paraffin: TDP-43/TARDBP Antibody (2E2-D3) [H00023435-M01] - Analysis of monoclonal antibody to TARDBP on formalin-fixed paraffin-embedded human leiomyosarcoma tissue Antibody concentration 3 ug/ml.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-2E2-D3-Immunohistochemistry-Paraffin-H00023435-M01-img0021.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: TDP-43/TARDBP Antibody (2E2-D3) [H00023435-M01] - Analysis of TARDBP over-expressed 293 cell line, cotransfected with TARDBP Validated Chimera RNAi ( Cat # H00023435-R01V ) (Lane 2) or non-transfected control (Lane 1). Blot probed with TARDBP monoclonal antibody (M01), clone 2E2-D3 (Cat # H00023435-M01 ). GAPDH ( 36.1 kDa ) used as specificity and loading control.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-2E2-D3-Western-Blot-H00023435-M01-img0023.jpg)
![ELISA: TDP-43/TARDBP Antibody (2E2-D3) [H00023435-M01] - Detection limit for recombinant GST tagged TARDBP is 0.3 ng/ml as a capture antibody.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-2E2-D3-ELISA-H00023435-M01-img0027.jpg)
![Western Blot: TDP-43/TARDBP Antibody (2E2-D3) [H00023435-M01] - PDI co-precipitates with TDP-43 & is increased in mutant TDP-43 transgenic mouse spinal cords.(A) Co-immunoprecipitation of wildtype & mutant Q331K TDP-43-mCherry from Neuro2a cell lysates using an anti-PDI antibody followed by TDP-43 immunoblot. Control immunoprecipitations performed using untransfected (Untrans) or mCherry expressing cell lysates, buffer only with coprecipitating antibodies or TDP-43 Q331K cell lysates using an irrelevant, isotype-matched control antibody (IgG). Input control (2%) shows expression of mCherry-TDP43 in wildtype & Q331K cell lysates. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0081170), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00023435-m01_mouse-monoclonal-tdp-43-tardbp-antibody-2e2-d3-310202415284521.jpg)
![Western Blot: TDP-43/TARDBP Antibody (2E2-D3) [H00023435-M01] - CLIP shows that TDP-43 directly interacts with translational target mRNAs. (A) Schematic diagram of the CLIP experiment. (B) Immunoblot showing specific IP of TDP-43 from MN1 cells under CLIP conditions. A TDP-43 band is specifically observed in the input & TDP-43 IP lanes from both untreated & UV-treated cells, but not in the IgG or anti-RBP X control lanes. RBP X is an IP of a different RNA-binding protein, which serves as an additional specificity control here. (C and D) Plots showing percentage of input mRNA in the TDP-43 IP for the mRNAs indicated in three separate CLIP assays from MN1 cells. Performing CLIP from UV-treated cells leads to significant recovery & enrichment relative to Gapdh for all mRNAs examined (C). In the absence of UV treatment, much less mRNA is recovered & no significant enrichment relative to Gapdh mRNA is observed. Note that the Y-axis scale in D is 1000× smaller than in C, indicating strong crosslinking dependence of mRNA co-immunoprecipitation (n = 3, s.e.m. error bars, P-values indicated in the plot, unpaired two-tailed t-test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30357366), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00023435-m01_mouse-monoclonal-tdp-43-tardbp-antibody-2e2-d3-310202415483647.jpg)
![Western Blot: TDP-43/TARDBP Antibody (2E2-D3) [H00023435-M01] - SINE compounds partially rescue motor deficits in an animal model of ALS/FTD. (a) Schematic timeline for in vivo experiments. (b) Western blot demonstrating the expression of human TDP43 within the brains of AAV9-injected animals, which we have previously shown is largely restricted to neuronal cell types (Jackson et al.59). Full-length blots appear in Fig. S1. (c) The hang test measures the time it takes for animals to fall from grid-like scaffold when it is lifted & tilted. A single representative animal administered AAV9-TDP43 is shown; note the inability of the hind limbs to clasp the wire mesh. (d) TDP43 expression impaired motor performance on the hang test at 3 weeks, an effect that could be mitigated by 7.5 mg kg-1 KPT-350. (e) Rotarod testing at 4 weeks of age showed prominent deficits associated with TDP43 expression that were resistant to treatment with SINE compounds. n, number of animals per condition. ns, not significant, mean ± s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA with Bonferroni correction. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-22858-w), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00023435-m01_mouse-monoclonal-tdp-43-tardbp-antibody-2e2-d3-310202415482260.jpg)
![Immunocytochemistry/ Immunofluorescence: beta Amyloid Antibody (MOAB-2) - BSA Free [NBP2-13075] - No difference in A beta plaque load between propofol (n = 8) & vehicle (n = 6) treated APP/PS1 mice. a An example image of A beta plaque immunoreactivity in the cortex of an APP/PS1 mouse following repeated propofol exposure. b A representative image of A beta plaque immunolabeling the cortex of an APP/PS1 mouse following treatment with vehicle. c Bar graph showing the percentage of the cortex occupied by A beta plaques in propofol & vehicle treated APP/PS1 mice. d Bar graph showing the average size (μm2) of A beta plaques in the cortex of APP/PS1 in the propofol & vehicle treatment groups. e Bar graph showing the average density of A beta plaques (/μm2) in the cortex of propofol & vehicle exposed APP/PS1 mice. All data is shown as mean ± SEM. Scale bar = 500 μm Image collected & cropped by CiteAb from the following publication (//bmcanesthesiol.biomedcentral.com/articles/10.1186/s12871-018-0509-5), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-13075_mouse-monoclonal-beta-amyloid-antibody-moab-2-310202416114798.jpg)
![Immunocytochemistry/Immunofluorescence: Synapsin I Antibody [NB300-104] - hPDLSCs-derived neural-like cells are connected by synapse-like interactions. hPDLSCs-derived neural-like cells connect to one another. Synapse-associated protein Synapsin1 is found in the cell membrane of hPDLSCs-derived neural-like cells at the neurite contact areas. Scale bar: 25 um. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-54745-3) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Synapsin-I-Antibody-Immunocytochemistry-Immunofluorescence-NB300-104-img0013.jpg "Immunocytochemistry/Immunofluorescence: Synapsin I Antibody [NB300-104] - hPDLSCs-derived neural-like cells are connected by synapse-like interactions. hPDLSCs-derived neural-like cells connect to one another. Synapse-associated protein Synapsin1 is found in the cell membrane of hPDLSCs-derived neural-like cells at the neurite contact areas. Scale bar: 25 um. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-54745-3) licensed under a CC-BY license.")
![<b>Orthogonal Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: Synapsin I Antibody [NB300-104] - Characterization of WT and slow ESCs differentiated to neurons. Immunofluorescence staining for neuronal markers Map2, and Syn1 in neurons cultured on poly-ornithine-/laminin-coated plates. Expression of neuronal markers in neurons cultured on poly-ornithine-/laminin-coated plates from RNA-seq analysis, n = 3. Image collected and cropped by CiteAb from the following publication (//onlinelibrary.wiley.com/doi/10.15252/embj.2018101244) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Synapsin-I-Antibody-Immunocytochemistry-Immunofluorescence-NB300-104-img0014.jpg)
![Western Blot: Synapsin I Antibody [NB300-104] - Western blot analysis showing induced expression of neuronal functional marker Synapsin I at protein levels in MNC (meningial neuronal construct). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30443545/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Synapsin I Antibody-Western Blot-NB300-104-img0015.jpg)
![Immunohistochemistry-Paraffin: Synapsin I Antibody [NB300-104] - Human cerebellum section, formalin fixed paraffin embedded. Stained with Synpasin-1 at 1:250. Citrate antigen retrieval at pH 6. Image from verified customer review.](http://images.novusbio.com/fullsize/Synapsin-I-Antibody-Immunohistochemistry-Paraffin-NB300-104-img0012.jpg)
![Western Blot: Synapsin I Antibody [NB300-104] - 10 ug of rat hippocampal (Hipp) lysate showing specific immunolabeling of the ~78k synapsin I doublet protein.](http://images.novusbio.com/fullsize/Synapsin-I-Antibody-Western-Blot-NB300-104-img0007.jpg)
![Western Blot: Synapsin I Antibody [NB300-104] - 10 ug of rat brain lysate showing specific immunolabeling of the ~78 kDa Synapsin I doublet.](http://images.novusbio.com/fullsize/Synapsin-I-Antibody-Western-Blot-NB300-104-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: Synapsin I Antibody [NB300-104] - ICC-IF validation analysis of Synapsin 1 Antibody on cultured rat caudate neurons. This representative image shows the punctate distribution of Synapsin 1 (green) and MAP (red) proteins in a neuronal cell.](http://images.novusbio.com/fullsize/Synapsin-I-Antibody-Immunocytochemistry-Immunofluorescence-NB300-104-img0011.jpg)
![Immunocytochemistry/ Immunofluorescence: Synapsin I Antibody [NB300-104] - Characterization of WT & slow ESCs differentiated to neurons (related to Fig 4)Immunofluorescence staining for neuronal markers Map2, Syn1, & NeuN in neurons cultured on poly‐ornithine‐/laminin‐coated plates.Expression of neuronal markers in neurons cultured on poly‐ornithine‐/laminin‐coated plates from RNA‐seq analysis, n = 3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30988016), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-104_rabbit-polyclonal-synapsin-i-antibody-310202415394528.jpg)
![Immunocytochemistry/ Immunofluorescence: Synapsin I Antibody [NB300-104] - hPDLSCs-derived neural-like cells are connected by synapse-like interactions. hPDLSCs-derived neural-like cells connect to one another (a) through different types of synapses-like interactions, including dendrodendritic-like, axoaxonic-like & axodendritic-like synapses (b). (c) Synapse-associated proteins Cx43, Synaptophysin & Synapsin1 are found in the cell membrane of hPDLSCs-derived neural-like cells at the neurite contact areas. Scale bar: 25 μm. AA, axoaxonic-like synapse; AD, axodendritic-like synapse; DD, dendrodendritic-like synapse; LM, light microscopy; SEM, scanning electron microscopy. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31792338), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-104_rabbit-polyclonal-synapsin-i-antibody-310202415371980.jpg)
![Western Blot: Synapsin I Antibody [NB300-104] - Synaptic localization of TA at the PC–PF synaptic contacts.Western blot of TA, V1, V2, VGAT proteins in cerebellar synaptosomal fractions (SYN) from P14 mice. Synaptosomal preparations are enriched of post synaptic density protein (PSD95) & Synapsin-I (Syn-I) in comparison to equal amount (ACT) of total cerebellar protein extract (LYS). TA is clearly present in synaptosomal enriched preparations. B) Cerebellar sagittal section immunostained for Cb (green), V1 (cyan) & TA (red). In the ML, anti-V1 specifically labels PF-terminals contacting PC-spines. C–E) The high magnification of the inset in B is reproduced in different merge images & by the relative split channels. C) Merge image of Cb & V1 staining plus the colocalization mask Cb/V1 (mCb/V1 in white); it represents the negative CTR (CTR-). D) Merge image of TA & Cb staining plus the colocalization mask TA/Cb (mTA/Cb in white), highlighting TA expression in PC-spines. E) Merge image of TA & V1 staining plus the colocalization mask TA/V1 (m TA/V1 in white), indicating the presence of TA also in this synaptic terminal. F) Quantitative colocalization analysis shows the mean overlap coefficients of TA/Cb (gray column) & TA/V1 (black column) significantly different from the negative CTR Cb/V1 (white column). The small insets (white boxes in C–D-E) are high magnifications of a representative PC-spine (green) contacted by a PF synaptic terminal (cyan) with the appropriate colocalization mask (white). * p < 0.05. Data are represented as mean ± SEM. Scale bars in B, 10 µm; in C–D-E, 5 µm; in F, 1 µm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23840813), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-104_rabbit-polyclonal-synapsin-i-antibody-31020241621237.jpg)
![Western Blot: Synapsin I Antibody [NB300-104] - Tau oligomers induce synaptic dysfunction. (A) Representative Western blot of mouse hippocampus homogenate. The levels of synaptophysin, synapsin-1, & septin-11 were measured by band quantification & normalized with the levels of tubulin. PBSo indicates representative bands of hippocampal area injected with PBS in mice also injected with tau oligomers, PBSf indicates PBS injection in mice also injected with tau fibrils, & PBSm indicates PBS injection in mice also injected with tau monomers. (B) Synaptophysin levels were significantly lower in the hemispheres injected with tau oligomers in comparison with the ones injected with fibrils, monomers, or PBS. (C) No significant differences in the levels of synapsin-1 were observed. (D) Only the hemisphere injected with tau oligomers presents a decrease in the level of septin-11. Data are represented as the mean ± SE. *p < 0.01, n = 6 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21645391), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-104_rabbit-polyclonal-synapsin-i-antibody-31020241620516.jpg)
![Western Blot: LRRK2 Antibody [NB300-268] - Western blotting of LRRK2. Recombinant LRRK2 (arrowhead) from transfected (+) HEK 293T and M17 cells was specifically recognized by all four LRRK2 antibodies (Ab1, Ab2, Ab3, and Ab4) used in this study. LRRK2 was not recognized in non-transfected cells (-). Image collected and cropped by CiteAb from the following publication (//molecularneurodegeneration.biomedcentral.com/articles/10.1186/1750-1326-1-17), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Western-Blot-NB300-268-img0023.jpg "<b>Independent Antibodies Validation. </b>Western Blot: LRRK2 Antibody [NB300-268] - Western blotting of LRRK2. Recombinant LRRK2 (arrowhead) from transfected (+) HEK 293T and M17 cells was specifically recognized by all four LRRK2 antibodies (Ab1, Ab2, Ab3, and Ab4) used in this study. LRRK2 was not recognized in non-transfected cells (-). Image collected and cropped by CiteAb from the following publication (//molecularneurodegeneration.biomedcentral.com/articles/10.1186/1750-1326-1-17), licensed under a CC-BY license.")
![<b>Independent Antibodies Validation. </b>Immunohistochemistry-Frozen: LRRK2 Antibody [NB300-268] - Staining as described in PMID 24312256. Image from verified customer review.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunohistochemistry-Frozen-NB300-268-img0014.jpg)
![Western Blot: LRRK2 Antibody [NB300-268] - LRRK2 N-terminal sequences show increased aggregation. Western blots of cell lysates of SH-SY5Y cells transfected with indicated LRRK2 construct showed equal expression of the LRRK2 protein with anti-HA (top panel) or anti-C-terminal- (bottom panel) LRRK2 antibody. Equal lysate loading is indicated by Beta-actin loading control. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0045149) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Western-Blot-NB300-268-img0028.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody [NB300-268] - Specificity of immunostaining for LRRK2. Specificity of the antibodies used for immunocytochemistry was determined by performing adsorptions with the corresponding peptide sequences. Immunochemical localization of LBs (arrows) by Ab1 against LRRK2900-100 (left) was blocked using respective peptide antigens (right). Adjacent sections with LB within pigmented neurons from the substantia nigra of a case of PD were used. Scale bar: 20 um. Image collected and cropped by CiteAb from the following publication (//molecularneurodegeneration.biomedcentral.com/articles/10.1186/1750-1326-1-17), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunohistochemistry-Paraffin-NB300-268-img0026.jpg)
![<b>Independent Antibodies Validation. </b>Immunohistochemistry-Paraffin: LRRK2 Antibody [NB300-268] - Immunocytochemistry of LRRK2 in PD using antibodies (Ab1, Ab4) raised against sequences corresponding to various regions shown on the schematic diagram of LRRK2 (red bars) were used on brainstem sections of PD. Scale bars: 10 um (top); E-L = 100 um (bottom). Image collected and cropped by CiteAb from the following publication (//molecularneurodegeneration.biomedcentral.com/articles/10.1186/1750-1326-1-17), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunohistochemistry-Paraffin-NB300-268-img0025.jpg)
![Flow Cytometry: LRRK2 Antibody [NB300-268] - Analysis using the Alexa Fluor 647 conjugate of NB300-268. Staining of LRRK2 in normal human peripheral blood cells (anticoagulated Lithium-Heparin) using anti-LRRK2 antibody conjugated with AF647. The primary antibody was used at a dilution of 1:200 and incubated for 20 min at room temperature. Image from verified customer review.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Flow-Cytometry-NB300-268-img0019.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody [NB300-268] - LRRK2 accumulates in globules in alphaS tg mice. Triple immunofluorescence for alphaS, LRRK2 and Rab5B for basal ganglia in alphaS tg mice. LRRK2 and Rab5B were colocalized in axon terminal (arrow), but were not colocalized in the alphaS-globule (arrowhead) Scale bar = 10 um for all panels. Image collected and cropped by CiteAb from the following publication (//molecularbrain.biomedcentral.com/articles/10.1186/1756-6606-5-34), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunohistochemistry-Paraffin-NB300-268-img0024.jpg)
![Immunocytochemistry/Immunofluorescence: LRRK2 Antibody [NB300-268] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-LRRK2 Antibody NB300-268 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunocytochemistry-Immunofluorescence-NB300-268-img0031.jpg)
![Flow Cytometry: LRRK2 Antibody [NB300-268] - An intracellular stain was performed on U2OS cells with LRRK2 Antibody NB300-268 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/LRRK2-Antibody-Flow-Cytometry-NB300-268-img0030.jpg)
![Immunocytochemistry/Immunofluorescence: LRRK2 Antibody [NB300-268] - LRRK2 antibody was tested in SH-SY-5Y cells at a 1:200 dilution against DyLight 488 (Green). Alpha tubulin and nuclei were counterstained against DyLight 568 (Red), and DAPI (Blue), respectively.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunocytochemistry-Immunofluorescence-NB300-268-img0015.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody [NB300-268] - Staining of human brain, Putamen, Neurons and Glia using a 60X magnification.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Immunohistochemistry-Paraffin-NB300-268-img0020.jpg)
![Flow Cytometry: LRRK2 Antibody [NB300-268] - An intracellular stain was performed on U2OS cells with LRRK Antibody NB300-268AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/LRRK2-Antibody-Flow-Cytometry-NB300-268-img0022.jpg)
![Flow Cytometry: LRRK2 Antibody [NB300-268] - An intracellular stain was performed on Neuro2a cells with LRRK2 Antibody NB300-268 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/LRRK2-Antibody-Flow-Cytometry-NB300-268-img0029.jpg)
![Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - Western blotting of LRRK2. A. Recombinant LRRK2 (arrowhead) from transfected (+) HEK 293T & M17 cells was specifically recognized by all four LRRK2 antibodies (Ab1, Ab2, Ab3, & Ab4) used in this study. LRRK2 was not recognized in non-transfected cells (-). B. Recombinant LRRK2 (arrowhead) from transfected M17 cells is detected by anti-LRRK2 Ab4 (lane 1), but not after absorption of the antibody with its peptide antigen (lane 2). Brain LRRK2 was recognized by anti-LRRK2 Ab4 in two controls (lanes 3 & 4) & two PD cases (lanes 5 & 6). Cell lysates (10 μg protein) & brain homogenates (100 μg protein) were prepared & loaded on 6% SDS-PAGE gels for Western blot analysis using anti-LRRK2 antibodies Ab1–Ab4 in (A) & Ab4 in (B). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415371926.jpg)
![Flow Cytometry: LRRK2 Antibody - BSA Free [NB300-268] - Deletion of LRRK2 attenuates Mn-induced apoptosis & cell death in RAW 264.7 cells.(A) LRRK2 WT or KO RAW 264.7 cells were treated with Mn (250 μM) for the designated times, followed by flow cytometry analysis to determine Mn-induced apoptosis. Both early & late apoptotic cells (Q2 & Q3) were measured. (B) At the end of Mn exposure, cell viability was determined by MTT assay. @@@, p < 0.001; ###, p < 0.001; ***, p < 0.001 compared to the control (one-way ANOVA followed by Tukey’s post hoc test; n = 3, for apoptosis assay; n = 6, for MTT assay). The data shown are representative of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30645642), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241539739.jpg)
![Immunocytochemistry/ Immunofluorescence: LRRK2 Antibody - BSA Free [NB300-268] - LRRK2 accumulates in globules in alpha S tg mice. (a & b) Double immunofluorescence for alpha S with parkin, PINK1, DJ-1, LRRK2, or negative control (the immunopeptide-preabsorbed anti-LRRK2 antibody) in alpha S tg mice (a) & P123H beta S tg mice (b). Note that alpha S-globules were immunopositive for LRRK2 (~79%, n = 22), whereas P123H beta S globules were negative for LRRK2. Representative images are shown for the thalamus ( alpha S) & basal ganglia (P123H beta S). Scale bar = 5 μm for all panels. (c) Triple immunofluorescence for alpha S, LRRK2 & Rab5B for basal ganglia in alpha S tg mice. LRRK2 & Rab5B were colocalized in axon terminal (arrow), but were not colocalized in the alpha S-globule (arrowhead) Scale bar = 10 μm for all panels. Image collected & cropped by CiteAb from the following publication (//molecularbrain.biomedcentral.com/articles/10.1186/1756-6606-5-34), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241538242.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Specificity of immunostaining for LRRK2. Specificity of the antibodies used for immunocytochemistry was determined by performing adsorptions with the corresponding peptide sequences. Immunochemical localization of LBs (arrows) by Ab4 against LRRK22500–2527 (A) & Ab1 against LRRK2900–100 (C) was blocked using respective peptide antigens (B & D). Adjacent sections with LB within pigmented neurons from the substantia nigra of a case of PD were used. Scale bar: 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415392599.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in DLB. Cortical LBs (arrows) in DLB were positive for LRRK2 using both Ab4 against LRRK22500–2527 (A), & Ab1 against LRRK2900–100 (B). Neuronal cytoplasm (C) was also strongly labelled throughout the cortex by Ab4 & with a consistently more granular pattern by Ab1 (inset in C) in cases of DLB. Control cases display similar, though less intense neuronal labeling (D). Biochemically purified cortical LBs were strongly positive for staining by Ab4 (E) as well as by anti-alpha -synuclein (F), while they were unstained when omitting primary antibody (G). Large vessels (H) were also intensely labelled by Ab4. Scale bars: A, B = 25 μm; C, D = 100 μm; E-G = 25 μm; H = 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415304221.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in DLB. Cortical LBs (arrows) in DLB were positive for LRRK2 using both Ab4 against LRRK22500–2527 (A), & Ab1 against LRRK2900–100 (B). Neuronal cytoplasm (C) was also strongly labelled throughout the cortex by Ab4 & with a consistently more granular pattern by Ab1 (inset in C) in cases of DLB. Control cases display similar, though less intense neuronal labeling (D). Biochemically purified cortical LBs were strongly positive for staining by Ab4 (E) as well as by anti-alpha -synuclein (F), while they were unstained when omitting primary antibody (G). Large vessels (H) were also intensely labelled by Ab4. Scale bars: A, B = 25 μm; C, D = 100 μm; E-G = 25 μm; H = 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241534387.jpg)
![Immunocytochemistry/ Immunofluorescence: LRRK2 Antibody - BSA Free [NB300-268] - LRRK2 accumulates in globules in alpha S tg mice. (a & b) Double immunofluorescence for alpha S with parkin, PINK1, DJ-1, LRRK2, or negative control (the immunopeptide-preabsorbed anti-LRRK2 antibody) in alpha S tg mice (a) & P123H beta S tg mice (b). Note that alpha S-globules were immunopositive for LRRK2 (~79%, n = 22), whereas P123H beta S globules were negative for LRRK2. Representative images are shown for the thalamus ( alpha S) & basal ganglia (P123H beta S). Scale bar = 5 μm for all panels. (c) Triple immunofluorescence for alpha S, LRRK2 & Rab5B for basal ganglia in alpha S tg mice. LRRK2 & Rab5B were colocalized in axon terminal (arrow), but were not colocalized in the alpha S-globule (arrowhead) Scale bar = 10 μm for all panels. Image collected & cropped by CiteAb from the following publication (//molecularbrain.biomedcentral.com/articles/10.1186/1756-6606-5-34), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241517133.jpg)
![Immunocytochemistry/ Immunofluorescence: LRRK2 Antibody - BSA Free [NB300-268] - LRRK2 accumulates in globules in alpha S tg mice. (a & b) Double immunofluorescence for alpha S with parkin, PINK1, DJ-1, LRRK2, or negative control (the immunopeptide-preabsorbed anti-LRRK2 antibody) in alpha S tg mice (a) & P123H beta S tg mice (b). Note that alpha S-globules were immunopositive for LRRK2 (~79%, n = 22), whereas P123H beta S globules were negative for LRRK2. Representative images are shown for the thalamus ( alpha S) & basal ganglia (P123H beta S). Scale bar = 5 μm for all panels. (c) Triple immunofluorescence for alpha S, LRRK2 & Rab5B for basal ganglia in alpha S tg mice. LRRK2 & Rab5B were colocalized in axon terminal (arrow), but were not colocalized in the alpha S-globule (arrowhead) Scale bar = 10 μm for all panels. Image collected & cropped by CiteAb from the following publication (//molecularbrain.biomedcentral.com/articles/10.1186/1756-6606-5-34), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415304292.jpg)
![Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - Western blotting of LRRK2. A. Recombinant LRRK2 (arrowhead) from transfected (+) HEK 293T & M17 cells was specifically recognized by all four LRRK2 antibodies (Ab1, Ab2, Ab3, & Ab4) used in this study. LRRK2 was not recognized in non-transfected cells (-). B. Recombinant LRRK2 (arrowhead) from transfected M17 cells is detected by anti-LRRK2 Ab4 (lane 1), but not after absorption of the antibody with its peptide antigen (lane 2). Brain LRRK2 was recognized by anti-LRRK2 Ab4 in two controls (lanes 3 & 4) & two PD cases (lanes 5 & 6). Cell lysates (10 μg protein) & brain homogenates (100 μg protein) were prepared & loaded on 6% SDS-PAGE gels for Western blot analysis using anti-LRRK2 antibodies Ab1–Ab4 in (A) & Ab4 in (B). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241536376.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in DLB. Cortical LBs (arrows) in DLB were positive for LRRK2 using both Ab4 against LRRK22500–2527 (A), & Ab1 against LRRK2900–100 (B). Neuronal cytoplasm (C) was also strongly labelled throughout the cortex by Ab4 & with a consistently more granular pattern by Ab1 (inset in C) in cases of DLB. Control cases display similar, though less intense neuronal labeling (D). Biochemically purified cortical LBs were strongly positive for staining by Ab4 (E) as well as by anti-alpha -synuclein (F), while they were unstained when omitting primary antibody (G). Large vessels (H) were also intensely labelled by Ab4. Scale bars: A, B = 25 μm; C, D = 100 μm; E-G = 25 μm; H = 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415175254.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in DLB. Cortical LBs (arrows) in DLB were positive for LRRK2 using both Ab4 against LRRK22500–2527 (A), & Ab1 against LRRK2900–100 (B). Neuronal cytoplasm (C) was also strongly labelled throughout the cortex by Ab4 & with a consistently more granular pattern by Ab1 (inset in C) in cases of DLB. Control cases display similar, though less intense neuronal labeling (D). Biochemically purified cortical LBs were strongly positive for staining by Ab4 (E) as well as by anti-alpha -synuclein (F), while they were unstained when omitting primary antibody (G). Large vessels (H) were also intensely labelled by Ab4. Scale bars: A, B = 25 μm; C, D = 100 μm; E-G = 25 μm; H = 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415345320.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in DLB. Cortical LBs (arrows) in DLB were positive for LRRK2 using both Ab4 against LRRK22500–2527 (A), & Ab1 against LRRK2900–100 (B). Neuronal cytoplasm (C) was also strongly labelled throughout the cortex by Ab4 & with a consistently more granular pattern by Ab1 (inset in C) in cases of DLB. Control cases display similar, though less intense neuronal labeling (D). Biochemically purified cortical LBs were strongly positive for staining by Ab4 (E) as well as by anti-alpha -synuclein (F), while they were unstained when omitting primary antibody (G). Large vessels (H) were also intensely labelled by Ab4. Scale bars: A, B = 25 μm; C, D = 100 μm; E-G = 25 μm; H = 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415384173.jpg)
![Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - LRRK2 deletion attenuates Mn-induced pro-apoptotic protein levels.(A) After cells (LRRK2 WT & LRRK2 KO) were exposed to Mn (250 μM) for up to 24 h, total protein was extracted & followed by western blot analysis to determine protein levels of Bax & Daxx. beta -actin was used as a loading control. (B) The expression levels of Bax & Daxx modulated by Mn were quantified relative to its control levels in LRRK2 WT & KO cells. **, p < 0.01; ***, p < 0.001 (one-way ANOVA followed by Tukey’s post hoc test; n = 3). The data shown are representative of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30645642), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241535611.jpg)
![Immunocytochemistry/ Immunofluorescence: LRRK2 Antibody - BSA Free [NB300-268] - The interaction & phosphorylation of LRRK2 & LC1. (A) Cellular co-localisation of endogenous LRRK2 & MAP1B (LC1). SKNSH cells were labelled with LRRK2 (green) & LC1 (red) antibodies & signals were detected by immunofluorescence. Detailed figure in Additional file 1. (B) LRRK2 kinase assay. The LRRK2 wild-typed (WT) kinase interacted & phosphorylated the LC1 domain unlike the LRRK2 kinase-dead protein. (C) Western blotting of LRRK2 & LC1 proteins after a kinase assay. Both LRRK2 & LC1 proteins were probed for phospho-threonine & phospho-serine signals respectively. Image collected & cropped by CiteAb from the following publication (//molecularbrain.biomedcentral.com/articles/10.1186/1756-6606-7-29), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202415382414.jpg)
![Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - Mn increases LRRK2 kinase activity & expression in RAW 264.7 & HMC3 cells.(A) Two-hundred (200) μg of protein were collected from cell lysates, followed by western blot analysis to determine the presence of LRRK2 in LRRK2 WT, KO RAW 264.7 & HMC3 cells. beta -actin was used as a loading control. (B,C) LRRK2 WT or HMC3 cells were treated with Mn (250 μM) for the designated times, followed by protein extraction & western blot analysis as described in the Methods section. Protein levels of LRRK2 & phosphorylated LRRK2 (S1292) in LRRK2 WT RAW 264.7 (B) & HMC3 (C) cells were quantified. (D,E) Effect of Mn on LRRK2 mRNA levels in LRRK2 WT RAW 264.7 (D) & HMC3 (E) cells were assessed as described in the Methods section. GAPDH was used as a loading control. (F) After pre-treatment with LRRK2 inhibitors GSK (1 μM) & MLi-2 (50 nM) for 90 min, RAW 264.7 cells were exposed to Mn (250 μM) for 20 min, followed by western blot analysis to detect phosphorylation of LRRK2 (S1292). ###, p < 0.001; *, p < 0.05; **, p < 0.01; ***, p < 0.001 compared to the control (one-way ANOVA followed by Tukey’s post hoc test; n = 3). The data shown are representative of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30645642), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241621814.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in PD. Four antibodies raised against sequences corresponding to various regions shown on the schematic diagram of LRRK2 (red bars) were used on brainstem sections of PD (A-H) & age-matched controls (I-L). Intense immunolabeling of brainstem LBs in cases of PD was seen with Ab1 against LRRK2900–100 (A) & Ab4 against LRRK22500–2527(D). Both rim (A & D) & core (inset in D) of LBs were recognized. In contrast, LBs were not labelled in any case using antibodies directed against LRRK21246–1265 (Ab2, B) or LRRK21838–2133 (Ab3, C), for which the antigenic sites are located within the folded domains. The cell bodies of both pigmented & no-pigmented neurons (arrows) as well as axons (arrowheads) contain LRRK2, seen only using antibodies against sites outside the folded domains (Ab1, E & Ab4, H). In contrast, Ab4 staining was much less intense in control tissue (L). The muscle layer of both large & small vessels was consistently found to contain high levels of LRRK2 in almost all PD cases (seen in E, G, & H) & strikingly the vessels are the only structure immunolabeled with Ab3 recognizing LRRK21838–2133 in all cases studied (G & K). Ab2 to LRRK21246–1265 did not recognize LBs, cell bodies or vessels in any case (B, F, & J). Scale bars: A-D & inset = 10 μm; E-L = 100 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202416205168.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in PD. Four antibodies raised against sequences corresponding to various regions shown on the schematic diagram of LRRK2 (red bars) were used on brainstem sections of PD (A-H) & age-matched controls (I-L). Intense immunolabeling of brainstem LBs in cases of PD was seen with Ab1 against LRRK2900–100 (A) & Ab4 against LRRK22500–2527(D). Both rim (A & D) & core (inset in D) of LBs were recognized. In contrast, LBs were not labelled in any case using antibodies directed against LRRK21246–1265 (Ab2, B) or LRRK21838–2133 (Ab3, C), for which the antigenic sites are located within the folded domains. The cell bodies of both pigmented & no-pigmented neurons (arrows) as well as axons (arrowheads) contain LRRK2, seen only using antibodies against sites outside the folded domains (Ab1, E & Ab4, H). In contrast, Ab4 staining was much less intense in control tissue (L). The muscle layer of both large & small vessels was consistently found to contain high levels of LRRK2 in almost all PD cases (seen in E, G, & H) & strikingly the vessels are the only structure immunolabeled with Ab3 recognizing LRRK21838–2133 in all cases studied (G & K). Ab2 to LRRK21246–1265 did not recognize LBs, cell bodies or vessels in any case (B, F, & J). Scale bars: A-D & inset = 10 μm; E-L = 100 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202416205158.jpg)
![Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - Mn increases LRRK2 kinase activity & expression in RAW 264.7 & HMC3 cells.(A) Two-hundred (200) μg of protein were collected from cell lysates, followed by western blot analysis to determine the presence of LRRK2 in LRRK2 WT, KO RAW 264.7 & HMC3 cells. beta -actin was used as a loading control. (B,C) LRRK2 WT or HMC3 cells were treated with Mn (250 μM) for the designated times, followed by protein extraction & western blot analysis as described in the Methods section. Protein levels of LRRK2 & phosphorylated LRRK2 (S1292) in LRRK2 WT RAW 264.7 (B) & HMC3 (C) cells were quantified. (D,E) Effect of Mn on LRRK2 mRNA levels in LRRK2 WT RAW 264.7 (D) & HMC3 (E) cells were assessed as described in the Methods section. GAPDH was used as a loading control. (F) After pre-treatment with LRRK2 inhibitors GSK (1 μM) & MLi-2 (50 nM) for 90 min, RAW 264.7 cells were exposed to Mn (250 μM) for 20 min, followed by western blot analysis to detect phosphorylation of LRRK2 (S1292). ###, p < 0.001; *, p < 0.05; **, p < 0.01; ***, p < 0.001 compared to the control (one-way ANOVA followed by Tukey’s post hoc test; n = 3). The data shown are representative of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30645642), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202416205187.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - Mn increases LRRK2 kinase activity & expression in RAW 264.7 & HMC3 cells.(A) Two-hundred (200) μg of protein were collected from cell lysates, followed by western blot analysis to determine the presence of LRRK2 in LRRK2 WT, KO RAW 264.7 & HMC3 cells. beta -actin was used as a loading control. (B,C) LRRK2 WT or HMC3 cells were treated with Mn (250 μM) for the designated times, followed by protein extraction & western blot analysis as described in the Methods section. Protein levels of LRRK2 & phosphorylated LRRK2 (S1292) in LRRK2 WT RAW 264.7 (B) & HMC3 (C) cells were quantified. (D,E) Effect of Mn on LRRK2 mRNA levels in LRRK2 WT RAW 264.7 (D) & HMC3 (E) cells were assessed as described in the Methods section. GAPDH was used as a loading control. (F) After pre-treatment with LRRK2 inhibitors GSK (1 μM) & MLi-2 (50 nM) for 90 min, RAW 264.7 cells were exposed to Mn (250 μM) for 20 min, followed by western blot analysis to detect phosphorylation of LRRK2 (S1292). ###, p < 0.001; *, p < 0.05; **, p < 0.01; ***, p < 0.001 compared to the control (one-way ANOVA followed by Tukey’s post hoc test; n = 3). The data shown are representative of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30645642), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241621239.jpg)
![Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - Mn increases LRRK2 kinase activity & expression in RAW 264.7 & HMC3 cells.(A) Two-hundred (200) μg of protein were collected from cell lysates, followed by western blot analysis to determine the presence of LRRK2 in LRRK2 WT, KO RAW 264.7 & HMC3 cells. beta -actin was used as a loading control. (B,C) LRRK2 WT or HMC3 cells were treated with Mn (250 μM) for the designated times, followed by protein extraction & western blot analysis as described in the Methods section. Protein levels of LRRK2 & phosphorylated LRRK2 (S1292) in LRRK2 WT RAW 264.7 (B) & HMC3 (C) cells were quantified. (D,E) Effect of Mn on LRRK2 mRNA levels in LRRK2 WT RAW 264.7 (D) & HMC3 (E) cells were assessed as described in the Methods section. GAPDH was used as a loading control. (F) After pre-treatment with LRRK2 inhibitors GSK (1 μM) & MLi-2 (50 nM) for 90 min, RAW 264.7 cells were exposed to Mn (250 μM) for 20 min, followed by western blot analysis to detect phosphorylation of LRRK2 (S1292). ###, p < 0.001; *, p < 0.05; **, p < 0.01; ***, p < 0.001 compared to the control (one-way ANOVA followed by Tukey’s post hoc test; n = 3). The data shown are representative of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30645642), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241621810.jpg)
![Western Blot: LRRK2 Antibody - BSA Free [NB300-268] - LRRK2 kinase inhibition blocks Tat-induced S935 phosphorylation & inflammatory cytokine expression in BV-2 cells. (A) Western blot depicting pS935-LRRK2 & total LRRK2 protein levels 12 hours after saline or Tat-treatment ± LRRK2 kinase inhibition (LRRK2i). (B) Tat treatment significantly increased pS935-LRRK2, which was attenuated by LRRK2i. (C) We measured TNF-alpha , IL-6, MCP-1 & IL-10 mRNA levels by qRT-PCR 12 hours post saline or Tat treatment ± LRRK2i. LRRK2i attenuated Tat-induced TNF-alpha , IL-6, MCP-1 & IL-10 expression for all groups (*P <0.05, ***P <0.001, one way ANOVA, Newman-Keuls post-test). ANOVA, analysis of variance; LRRK2, leucine-rich repeat kinase2; pS935, phosphorylation of serine 935; Tat, trans activator of transcription. Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-9-261), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-310202416212357.jpg)
![Immunohistochemistry-Paraffin: LRRK2 Antibody - BSA Free [NB300-268] - Immunocytochemistry of LRRK2 in PD. Four antibodies raised against sequences corresponding to various regions shown on the schematic diagram of LRRK2 (red bars) were used on brainstem sections of PD (A-H) & age-matched controls (I-L). Intense immunolabeling of brainstem LBs in cases of PD was seen with Ab1 against LRRK2900–100 (A) & Ab4 against LRRK22500–2527(D). Both rim (A & D) & core (inset in D) of LBs were recognized. In contrast, LBs were not labelled in any case using antibodies directed against LRRK21246–1265 (Ab2, B) or LRRK21838–2133 (Ab3, C), for which the antigenic sites are located within the folded domains. The cell bodies of both pigmented & no-pigmented neurons (arrows) as well as axons (arrowheads) contain LRRK2, seen only using antibodies against sites outside the folded domains (Ab1, E & Ab4, H). In contrast, Ab4 staining was much less intense in control tissue (L). The muscle layer of both large & small vessels was consistently found to contain high levels of LRRK2 in almost all PD cases (seen in E, G, & H) & strikingly the vessels are the only structure immunolabeled with Ab3 recognizing LRRK21838–2133 in all cases studied (G & K). Ab2 to LRRK21246–1265 did not recognize LBs, cell bodies or vessels in any case (B, F, & J). Scale bars: A-D & inset = 10 μm; E-L = 100 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17137507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241621837.jpg)
![Flow Cytometry: LRRK2 Antibody - BSA Free [NB300-268] - Inhibition of LRRK2 kinase activity attenuates Mn-induced apoptosis.(A) After pre-treatment with GSK (1 μM) for 90 min, cells (HMC3) were exposed to Mn (250 μM) for the designated time periods, followed by annexin V & PI staining & flow cytometry analysis to determine apoptosis. Early & late apoptotic cells (Q2 & Q3) were analyzed. (B,C) After pre-treatment with GSK (1 μM) for 90 min, cells (LRRK2 WT RAW 264.7 & HMC3) were exposed to Mn for designated time periods, followed by the MTT assay to determine cell viability, as described in the Methods section, (@@@, p < 0.001; *, p < 0.05; ***, p < 0.001 compared to the control (one-way ANOVA followed by Tukey’s post hoc test; n = 3, apoptosis assay; n = 6, MTT assay). The data shown are representative of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30645642), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-268_rabbit-polyclonal-lrrk2-antibody-31020241621844.jpg)
![Immunohistochemistry-Paraffin: Apolipoprotein E/ApoE Antibody (WUE-4) [NB110-60531] - ApoE was detected in immersion fixed paraffin-embedded sections of human liver using anti-human mouse monoclonal antibody (Catalog # NB110-60531) at 1:200 dilution overnight at 4C. Tissue was stained using the VisuCyte anti-mouse HRP polymer detection reagent (Catalog # VC001) with DAB chromogen (brown) and counterstained with hematoxylin (blue). Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.](http://images.novusbio.com/fullsize/Apolipoprotein-E-ApoE-Antibody-WUE-4-Immunohistochemistry-Paraffin-NB110-60531-img0011.jpg "Immunohistochemistry-Paraffin: Apolipoprotein E/ApoE Antibody (WUE-4) [NB110-60531] - ApoE was detected in immersion fixed paraffin-embedded sections of human liver using anti-human mouse monoclonal antibody (Catalog # NB110-60531) at 1:200 dilution overnight at 4C. Tissue was stained using the VisuCyte anti-mouse HRP polymer detection reagent (Catalog # VC001) with DAB chromogen (brown) and counterstained with hematoxylin (blue). Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.")
![Western Blot: Apolipoprotein E/ApoE Antibody (WUE-4) [NB110-60531] - ApoE Antibody (WUE-4) [NB110-60531] - Detection of ApoE in human tissue lysate using NB110-60531. Lane 1: liver Lane 2: brain](http://images.novusbio.com/fullsize/Apolipoprotein-E-ApoE-Antibody-WUE-4-Western-Blot-NB110-60531-img0013.jpg)
![Flow Cytometry: Apolipoprotein E/ApoE Antibody (WUE-4) [NB110-60531] - ApoE Antibody (WUE-4) [NB110-60531] - Intracellular flow cytometric staining of 1 x 10^6 CHO (A) and HEK-293 (B) cells using ApoE antibody (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1x10^6 cells was used.](http://images.novusbio.com/fullsize/Apolipoprotein-E-ApoE-Antibody-WUE-4-Flow-Cytometry-NB110-60531-img0014.jpg)
![Western Blot: Apolipoprotein E/ApoE Antibody (WUE-4) [NB110-60531] - 50 ug protein per lane for liver lysate and 0.5 ul of plasma at 9% SDS. Samples are loaded onto the gel as the following order: human liver lysate, mouse liver lysate, rat liver lysate, human plasma, and mouse plasma. Image from confirmed customer review.](http://images.novusbio.com/fullsize/Apolipoprotein-E-ApoE-Antibody-WUE-4-Western-Blot-NB110-60531-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: Apolipoprotein E/ApoE Antibody (WUE-4) [NB110-60531] - HepG2 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti-ApoE (WUE-4) [NB110-60531] at a 1:200 dilution overnight at 4C and detected with an anti-mouse DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Apolipoprotein-E-ApoE-Antibody-WUE-4-Immunocytochemistry-Immunofluorescence-NB110-60531-img0010.jpg)
![Flow Cytometry: Apolipoprotein E/ApoE Antibody (WUE-4) [NB110-60531] - Analysis of apoB-positivity in blood plasma and PLT concentrate-derived EXOs. FCM detection of the indicated markers in EXOs conjugated onto latex beads. The EXOs were isolated from fasting PFP or PLT concentrate by differential UC and gravity size filtration (gray histograms: blocked beads incubated with antibody, empty histograms: EXO sample). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep24316), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Apolipoprotein-E-ApoE-Antibody-WUE-4-Flow-Cytometry-NB110-60531-img0020.jpg)
![Flow (Intracellular): Apolipoprotein E/ApoE Antibody (WUE-4) [NB110-60531] - An intracellular stain was performed on HepG2 cells with NB110-60531AF700 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 700.](http://images.novusbio.com/fullsize/Apolipoprotein-E-ApoE-Antibody-WUE-4-Flow-Intracellular-NB110-60531-img0012.jpg)
![Flow Cytometry: Apolipoprotein E/ApoE Antibody (WUE-4) [NB110-60531] - An intracellular stain was performed on HepG2 cells with NB110-60531PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin.](http://images.novusbio.com/fullsize/Apolipoprotein-E-ApoE-Antibody-WUE-4-Flow-Cytometry-NB110-60531-img0015.jpg)
![Flow Cytometry: Apolipoprotein E/ApoE Antibody (WUE-4) [NB110-60531] - An intracellular stain was performed on HepG2 cells with Apolipoprotein E/ApoE Antibody NB110-60531 [WUE-4] (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 488.](http://images.novusbio.com/fullsize/Apolipoprotein-E-ApoE-Antibody-WUE-4-Flow-Cytometry-NB110-60531-img0016.jpg)
![Flow Cytometry: Apolipoprotein E/ApoE Antibody (WUE-4) [NB110-60531] - An intracellular stain was performed on SK-MEL-28 cells with alpha-Synuclein [2A7] Antibody NB110-60531AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/Apolipoprotein-E-ApoE-Antibody-WUE-4-Flow-Cytometry-NB110-60531-img0017.jpg)
![Flow Cytometry: Apolipoprotein E/ApoE Antibody (WUE-4) [NB110-60531] - An intracellular stain was performed on SK-MEL-28 cells with Apolipoprotein E/ApoE Antibody [WUE-4] NB110-60531F (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to FITC.](http://images.novusbio.com/fullsize/Apolipoprotein-E-ApoE-Antibody-WUE-4-Flow-Cytometry-NB110-60531-img0018.jpg)
![Flow Cytometry: Apolipoprotein E/ApoE Antibody (WUE-4) [NB110-60531] - An intracellular stain was performed on SK-MEL-28 cells with Apolipoprotein E/ApoE [WUE-4] Antibody NB110-60531PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin.](http://images.novusbio.com/fullsize/Apolipoprotein-E-ApoE-Antibody-WUE-4-Flow-Cytometry-NB110-60531-img0019.jpg)
![Western Blot: STEP Antibody (23E5) [NB300-202] - Analysis of STEP protein in striatal rat protein homogenates](http://images.novusbio.com/fullsize/STEP-Antibody-23E5-Western-Blot-NB300-202-img0002.jpg "Western Blot: STEP Antibody (23E5) [NB300-202] - Analysis of STEP protein in striatal rat protein homogenates")
![Immunohistochemistry-Paraffin: STEP Antibody (23E5) [NB300-202] - STEP was detected in immersion fixed paraffin-embedded sections of human brain basal ganglia using Mouse Anti-Human STEP (23E5) Monoclonal Antibody (Catalog # NB300-202) at 1:100 for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm in neurons.](http://images.novusbio.com/fullsize/STEP-Antibody-23E5-Immunohistochemistry-Paraffin-NB300-202-img0003.jpg)
![Western Blot: PSD-95 Antibody (6G6-1C9) [NB300-556] - Analysis of 25 ug of mouse brain (lane 1) and rat brain (lane 2) cell lysates.](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Western-Blot-NB300-556-img0020.jpg "Western Blot: PSD-95 Antibody (6G6-1C9) [NB300-556] - Analysis of 25 ug of mouse brain (lane 1) and rat brain (lane 2) cell lysates.")
![Immunocytochemistry/Immunofluorescence: PSD-95 Antibody (6G6-1C9) [NB300-556] - Control immunolocalization of plasma membrane AMPA receptor subunits (external epitopes) in hippocampal neuronal cultures. H) Immunolabeling of non-permeabilized neuronal cultures with ani-GluA1 (green). (I) Immunolabeling with the postsynaptic marker anti-PSD95 [66] after permeabilization of neuronal cultures. (J) Merging of (H) and (I) showing postsynaptic labeling of GluA1. Scale bar (valid for all images): 10 um. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0140868), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Immunocytochemistry-Immunofluorescence-NB300-556-img0025.jpg)
![Immunohistochemistry-Paraffin: PSD-95 Antibody (6G6-1C9) [NB300-556] - Confocal images of dissociated hippocampal cultures. Double labeling with anti-syntaxin-1 Double labeling with antibodies against syntaxin-1 (D) and synaptophysin (E) indicates that syntaxin-1 is colocalized with presynaptic marker (F). Image collected and cropped by CiteAb from the following publication (//journal.frontiersin.org/Article/10.3389/fnmol.2016.00010/abstract), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Immunohistochemistry-Paraffin-NB300-556-img0024.jpg)
![Flow Cytometry: PSD-95 Antibody (6G6-1C9) [NB300-556] - An intracellular stain was performed on HeLa cells with PSD-95 Antibody (6G6-1C9) NB300-556AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Flow-Cytometry-NB300-556-img0023.jpg)
![Immunocytochemistry/Immunofluorescence: PSD-95 Antibody (6G6-1C9) [NB300-556] - Analysis of PSD95 using PSD95 Monoclonal antibody (6G6-1C9) shows staining in HeLa cells. PSD95 staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with or an antibody recognizing PSD95 at a dilution of 1:100-1:200 over night at 4C, washed with PBS and incubated with a DyLight-488 conjugated.](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Immunocytochemistry-Immunofluorescence-NB300-556-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: PSD-95 Antibody (6G6-1C9) [NB300-556] - Analysis of PSD95 using PSD95 Monoclonal antibody (6G6-1C9) shows staining in U251 glioma cells. PSD95 staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with or an antibody recognizing PSD95 at a dilution of 1:100-1:200 over night at 4C, washed with PBS and incubated with a DyLight-488 conjugated.](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Immunocytochemistry-Immunofluorescence-NB300-556-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: PSD-95 Antibody (6G6-1C9) [NB300-556] - Analysis of PSD95 using PSD95 Monoclonal antibody (6G6-1C9) shows staining in C6 glioma cells. PSD95 staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with or an antibody recognizing PSD95 at a dilution of 1:100-1:200 over night at 4C, washed with PBS and incubated with a DyLight-488 conjugated.](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Immunocytochemistry-Immunofluorescence-NB300-556-img0018.jpg)
![Immunocytochemistry/Immunofluorescence: PSD-95 Antibody (6G6-1C9) [NB300-556] - Analysis of Post Synaptic Density 95kD protein (PSD95, green) in cultured primary cortical neurons. Primary cortical neurons are isolated and cultured using the Primary Neuron Isolation Kit. At day 28, neurons were fixed with 4% paraformaldehyde, permeablilized with 0.1% triton X-100 in HBSS for 10 minutes at room temperature, and blocked with 3% BSA in PBS for 30 minutes at room temperature. Cells were probed with a PSD95 monoclonal antibody at a dilution of 1:500 for 2 hours at room temperature or overnight at 4C, washed with HBSS, and incubated with DyLight 488 goat anti-mouse IgG secondary antibody at dilution of 1:500 for 1 hour at room temperature.](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Immunocytochemistry-Immunofluorescence-NB300-556-img0019.jpg)
![Immunocytochemistry/Immunofluorescence: PSD-95 Antibody (6G6-1C9) [NB300-556] - Mixed 3 week old rat cortical cultures (21 DIV) were labelled with anti-PSD95 (1:650) and visualised with anti-mouse Alexa647 (1:2000). The antibody labels small punctae along neuronal processes as expected. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Immunocytochemistry-Immunofluorescence-NB300-556-img0021.jpg)
![Flow Cytometry: PSD-95 Antibody (6G6-1C9) [NB300-556] - Analysis of PSD95 in Neuro-2a cells compared to an isotype control (blue).](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Flow-Cytometry-NB300-556-img0012.jpg)
![Flow Cytometry: PSD-95 Antibody (6G6-1C9) [NB300-556] - Analysis of PSD95 in SH-SY5Y cells compared to an isotype control (blue).](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Flow-Cytometry-NB300-556-img0013.jpg)
![Flow Cytometry: PSD-95 Antibody (6G6-1C9) [NB300-556] - Analysis of PSD95 in U87-MG cells compared to an isotype control (blue).](http://images.novusbio.com/fullsize/PSD-95-Antibody-6G6-1C9-Flow-Cytometry-NB300-556-img0014.jpg)
![Immunocytochemistry/ Immunofluorescence: PSD-95 Antibody (6G6-1C9) - BSA Free [NB300-556] - Confocal images of dissociated hippocampal cultures. Double labeling with anti-syntaxin-1 (A) & anti-Tuj1 (B) demonstrates that syntaxin-1 is located along the dendrites & gives characteristic punctate labeling (C). Double labeling with antibodies against syntaxin-1 (D) & synaptophysin (E) indicates that syntaxin-1 is colocalized with presynaptic marker (F). Double labeling for syntaxin-1 (G) & PSD-95 (H) shows partial colocalization postsynaptic (I). Scale bars: 10 μm. (J–L) Western blot analysis of synaptosomes (Syn), synaptic cytosolic fraction (Cy), active zone (AZ) & post synaptic density (PSD). Labeled with anti-synaptophysin (J) anti-PSD95 (K) & anti-syntaxin-1 (L). Image collected & cropped by CiteAb from the following publication (//journal.frontiersin.org/Article/10.3389/fnmol.2016.00010/abstract), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-556_mouse-monoclonal-psd-95-antibody-6g6-1c9-310202415392516.jpg)
![Western Blot: PSD-95 Antibody (6G6-1C9) - BSA Free [NB300-556] - Confocal images of dissociated hippocampal cultures. Double labeling with anti-syntaxin-1 (A) & anti-Tuj1 (B) demonstrates that syntaxin-1 is located along the dendrites & gives characteristic punctate labeling (C). Double labeling with antibodies against syntaxin-1 (D) & synaptophysin (E) indicates that syntaxin-1 is colocalized with presynaptic marker (F). Double labeling for syntaxin-1 (G) & PSD-95 (H) shows partial colocalization postsynaptic (I). Scale bars: 10 μm. (J–L) Western blot analysis of synaptosomes (Syn), synaptic cytosolic fraction (Cy), active zone (AZ) & post synaptic density (PSD). Labeled with anti-synaptophysin (J) anti-PSD95 (K) & anti-syntaxin-1 (L). Image collected & cropped by CiteAb from the following publication (//journal.frontiersin.org/Article/10.3389/fnmol.2016.00010/abstract), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-556_mouse-monoclonal-psd-95-antibody-6g6-1c9-310202415334924.jpg)
![Immunocytochemistry/ Immunofluorescence: PSD-95 Antibody (6G6-1C9) - BSA Free [NB300-556] - Confocal images of dissociated hippocampal cultures.Double labeling with anti-TUJ1 (A) & anti-VAMP2 (B) demonstrates that VAMP2 is located along the dendrites & gives characteristic punctate labeling (C). Double labeling with antibodies against synaptophysin (P38) (D) & VAMP2 (E) indicates that VAMP2 is colocalized with the presynaptic marker (F). Double labeling for PSD-95 (G) & VAMP2 (H) shows partial colocalization postsynaptic (I). Small, high-resolution pictures of single synapses from (F) & (I) are shown in the right part of these images, respectively. Scale bar: 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26488171), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-556_mouse-monoclonal-psd-95-antibody-6g6-1c9-310202415395948.jpg)
![Immunocytochemistry/ Immunofluorescence: PSD-95 Antibody (6G6-1C9) - BSA Free [NB300-556] - Control immunolocalization of plasma membrane AMPA receptor subunits (external epitopes) in hippocampal neuronal cultures.(A) Beta-tubulin (green, anti-TuJ1) labeling of dendrite, after anti-GluA1 external epitope [66] labeling & subsequent plasma membrane permeabilization. Note punctate GluA1 [66] labeling along the dendrite. (B) Synaptophysin (P38, green) & GluA1 [66]. (C) Synaptophysin (green) & GluA2 [66]. (D) Labeling with anti-GluA1. (E) Labeling with anti-GluA1, but the antibody was preincubated with the peptide antigen before staining. (F) Labeling with anti-GluA2. (G) Labeling with anti-GluA2, but the antibody was preincubated with the peptide antigen before staining. (H) Immunolabeling of non-permeabilized neuronal cultures with ani-GluA1 (green). (I) Immunolabeling with the postsynaptic marker anti-PSD95 [66] after permeabilization of neuronal cultures. (J) Merging of (H) & (I) showing postsynaptic labeling of GluA1. Scale bar (in A, valid for all images): 10 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26488171), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-556_mouse-monoclonal-psd-95-antibody-6g6-1c9-310202416205115.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - BDNF lowered the mechanical withdrawal threshold further and promoted activation of astrocytes and microglia, and enhanced the p38/JNK pathway to aggravate the release of IL-1beta and TNF-alpha in the SDH of CYP-induced cystitis. Western blots showing the expression of BDNF was further upregulated when compared with the CYP + PBS group. Data of mechanical withdrawal threshold were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean +/- SEM (n = 10 per group). **p < 0.01, ***p < 0.001 vs. the control group. #p < 0.05, ##p < 0.01, ###p < 0.001 vs. the CYP + rBDNF group. $p < 0.05, $$p < 0.01, $$$p < 0.001 vs. the CYP + PBS group.](http://images.novusbio.com/fullsize/BDNF-Antibody-Western-Blot-NB100-98682-img0010.jpg "<b>Biological Strategies Validation. </b>Western Blot: BDNF Antibody [NB100-98682] - BDNF lowered the mechanical withdrawal threshold further and promoted activation of astrocytes and microglia, and enhanced the p38/JNK pathway to aggravate the release of IL-1beta and TNF-alpha in the SDH of CYP-induced cystitis. Western blots showing the expression of BDNF was further upregulated when compared with the CYP + PBS group. Data of mechanical withdrawal threshold were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean +/- SEM (n = 10 per group). **p < 0.01, ***p < 0.001 vs. the control group. #p < 0.05, ##p < 0.01, ###p < 0.001 vs. the CYP + rBDNF group. $p < 0.05, $$p < 0.01, $$$p < 0.001 vs. the CYP + PBS group.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry: BDNF Antibody [NB100-98682] - Effects of mBMSC and EA treatment on the expression of mBDNF and NT4 in neurons. Photomicrographs for mBDNF/NeuN or NT4/NeuN double-positive cells in the striatum and hippocampus (n = 5). The number of mBDNF/NeuN double-positive cells in the SVZ + striatum and hippocampus was significantly higher in the EA-treated MCAO group and the combined mBMSC + EA-treated MCAO group, compared to the number in the other groups. The number of NT4/NeuN double-positive cells in the hippocampus was significantly higher in the EA-treated MCAO group than in the vehicle-treated MCAO group. #p < 0.05 and ##p < 0.01 versus control group; *p < 0.05, **p < 0.01, and ***p < 0.001 versus vehicle-treated MCAO group; &&p < 0.01 versus mBMSC-treated MCAO group. Scale bar = 100 um. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/s41598-018-20481-3) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/BDNF-Antibody-Immunohistochemistry-NB100-98682-img0007.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - Human platelet lysate and recombinant mature BDNF. Blocking: 1% LFDM for 30 min at RT; primary antibody (1:1000) incubated at 4C overnight.](http://images.novusbio.com/fullsize/BDNF-Antibody-Western-Blot-NB100-98682-img0006.jpg)
![Immunohistochemistry-Paraffin: BDNF Antibody [NB100-98682] - Mouse hippocampus. The animal was perfused at a pressure of 130 mmHg with 300 ml 4% FA before being processed for paraffin embedding. HIER: Tris-EDTA, pH 9 for 20 min. Blocking: 0.2% LFDM in TBST filtered thru 0.2 um. Detection was done using Novolink HRP polymer from Leica following manufacturers instructions; DAB chromogen: Candela DAB chromogen. Primary antibody: dilution 1: 1000, incubated 30 min at RT. Sections were counterstained with Harris Hematoxylin.](http://images.novusbio.com/fullsize/BDNF-Antibody-Immunohistochemistry-Paraffin-NB100-98682-img0001.jpg)
![Immunohistochemistry-Paraffin: BDNF Antibody [NB100-98682] - Mouse hippocampus. The animal was perfused at a pressure of 130 mmHg with 300 ml 4% FA before being processed for paraffin embedding. HIER: Tris-EDTA, pH 9 for 20 min. Blocking: 0.2% LFDM in TBST filtered thru 0.2 um. Detection was done using Novolink HRP polymer from Leica following manufacturers instructions; DAB chromogen: Candela DAB chromogen. Primary antibody: dilution 1: 1000, incubated 30 min at RT. Sections were counterstained with Harris Hematoxylin.](http://images.novusbio.com/fullsize/BDNF-Antibody-Immunohistochemistry-Paraffin-NB100-98682-img0003.jpg)
![Immunohistochemistry-Paraffin: BDNF Antibody [NB100-98682] - Mouse hippocampus. The animal was perfused at a pressure of 130 mmHg with 300 ml 4% FA before being processed for paraffin embedding. HIER: Tris-EDTA, pH 9 for 20 min. Blocking: 0.2% LFDM in TBST filtered thru 0.2 um. Detection was done using Novolink HRP polymer from Leica following manufacturers instructions; DAB chromogen: Candela DAB chromogen. Primary antibody: dilution 1: 1000, incubated 30 min at RT. Sections were counterstained with Harris Hematoxylin.](http://images.novusbio.com/fullsize/BDNF-Antibody-Immunohistochemistry-Paraffin-NB100-98682-img0005.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - Effect of treatment with FX extract on CREB/BDNF signaling. (a-c) Differences in the phosphorylation of CREB & expression of BDNF between groups in the PFC & hippocampus (n = 3-4). (d, e) pCREB & BDNF immunofluorescence was assessed in the PFC & hippocampus (n = 3-4). Mean ± SD. #P < 0.05 versus normal group; ∗P < 0.05 & ∗∗P < 0.01 versus control group. Scale bar = 200 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30065945), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202415371951.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - Effect of treatment with FX extract on CREB/BDNF signaling. (a-c) Differences in the phosphorylation of CREB & expression of BDNF between groups in the PFC & hippocampus (n = 3-4). (d, e) pCREB & BDNF immunofluorescence was assessed in the PFC & hippocampus (n = 3-4). Mean ± SD. #P < 0.05 versus normal group; ∗P < 0.05 & ∗∗P < 0.01 versus control group. Scale bar = 200 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30065945), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202415175223.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - Antagonized TrkB could restrain the activation of astrocytes & microglia & supress the p38/JNK pathway to alleviate the release of IL-1 beta & TNF-alpha in the SDH of CYP-induced cystitis. Western blots showed that the overexpression of a BDNF, b TrkB, cp-TrkB, d Iba1, e GFAP, fp-p38, gp-JNK, h TNF-alpha , & i IL-1 beta were downregulated in comparison to the CYP + DMSO group after ANA-12 treatment. All data were calculated as mean ± SEM (n = 5 per group). **p < 0.01, ***p < 0.001 vs. control group. ##p < 0.01, ###p < 0.001 vs. CYP + ANA-12 group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31931832), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202415291934.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - BDNF lowered the mechanical withdrawal threshold further & promoted activation of astrocytes & microglia, & enhanced the p38/JNK pathway to aggravate the release of IL-1 beta & TNF-alpha in the SDH of CYP-induced cystitis. a BDNF treated every other day after CYP injection could further lower the mechanical withdrawal threshold & suppress the retrieval of mechanical threshold when compared with the CYP + PBS group. After the exogenous BDNF injection, Western blots showing the expression of b BDNF, c TrkB, dp-TrkB, e Iba1, f GFAP, gp-p38, hp-JNK, i TNF-alpha , & j IL-1 beta were all further upregulated when compared with the CYP + PBS group. Data of mechanical withdrawal threshold were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean ± SEM (n = 10 per group). **p < 0.01, ***p < 0.001 vs. the control group. #p < 0.05, ##p < 0.01, ###p < 0.001 vs. the CYP + rBDNF group. $p < 0.05, $$p < 0.01, $$$p < 0.001 vs. the CYP + PBS group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31931832), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202416284921.jpg)
![Immunohistochemistry: BDNF Antibody [NB100-98682] - Effects of mBMSC & EA treatment on the expression of trophic factors. (A) Photomicrographs & (B‒D) histograms for mBDNF, NT4, & VEGF expression (n = 4–5). mBDNF expression was markedly increased by treatment with mBMSC and/or EA compared to vehicle treatment. mBDNF expression levels were higher in the EA-treated MCAO group than in the mBMSC-treated MCAO group. NT4 expression in the SVZ & hippocampus was significantly higher in the combined mBMSC & EA treatment group than in the other groups. VEGF expression in the hippocampus was markedly higher in the mBMSC treatment group than in the vehicle-treated MCAO group. #p < 0.05, ##p < 0.01, & ###p < 0.001 versus control group; *p < 0.05, **p < 0.01, & ***p < 0.001 versus vehicle-treated MCAO group; &p < 0.05, &&p < 0.01, & &&&p < 0.001 versus mBMSC-treated MCAO group; Scale bar = 1 mm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29391466), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202416284912.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - The expression of BDNF-TrkB signaling in the SDH of CYP-induced cystitis. a Changes of the mechanical threshold in CYP-induced cystitis model. Compared to that in the control group, the mechanical threshold of the cystitis group decreased significantly after the CYP injection & remained low until day 17, & the minimum threshold value was reached on day 12. The expression of b BDNF, c TrkB, & dp-TrkB were evaluated by western blots. Compared to the control group, they were upregulated on days 8, 12, & 17. e Immunofluorescence double staining assay of BDNF & p-TrkB in the SDH. BDNF & p-TrkB (red), NeuN, GFAP, & OX-42( green), co-localization (yellow). BDNF was mainly colocalized in neurons which mainly located in Laminate II to IV. & TrkB receptors expressed in neurons, microglia, & astrocytes. The white dotted lines in picture “BDNF/NeuN” showed the laminate of the SDH according to Rexed & Steiner. Scale bar = 100 μm. All data were calculated as mean ± SEM (n = 5 per group). *p < 0.05, ** p < 0.01, *** p < 0.001 vs. the control group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31931832), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202416284910.jpg)
![Western Blot: FUS Antibody [NB100-565] - Western blot shows lysates of HEK293 human embryonic kidney parental cell line and FUS knockout (KO) HEK293 human embryonic kidney cell line. PVDF membrane was probed with 1:1000 of Rabbit Anti-Human FUS Polyclonal Antibody (Catalog # NB100-565) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog #HAF008). Specific band was detected for FUS at approximately 75 kDa (as indicated) in the parental HEK293 celll line, but is not detectable in the knockout HEK293 cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/FUS-Antibody-Knockout-Validated-NB100-565-img0020.jpg "<b>Genetic Strategies Validation. </b>Western Blot: FUS Antibody [NB100-565] - Western blot shows lysates of HEK293 human embryonic kidney parental cell line and FUS knockout (KO) HEK293 human embryonic kidney cell line. PVDF membrane was probed with 1:1000 of Rabbit Anti-Human FUS Polyclonal Antibody (Catalog # NB100-565) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog #HAF008). Specific band was detected for FUS at approximately 75 kDa (as indicated) in the parental HEK293 celll line, but is not detectable in the knockout HEK293 cell line. This experiment was conducted under reducing conditions.")
![<b>Genetic Strategies Validation. </b>Western Blot: FUS Antibody [NB100-565] - FUS activates GSK-3beta in transfected cells and transgenic mice A. Cells were transfected with either control vector (CTRL), HA-FUS, HA-FUSR521C or HA FUSR518K and the samples probed on immunoblots for GSK-3beta phosphorylated on serine 9 (GSK-3beta-S9), total GSK-3beta, FUS (using FUS antibody) and tubulin as a loading control. Phosphorylation of GSK-3beta serine 9 is the principal mechanism for regulating its activity; serine 9 phosphorylation inhibits GSK-3beta activity. Bar chart shows relative levels of GSK-3beta serine 9 phosphorylation following quantification of signals from immunoblots and normalization to total GSK-3beta signals. Data were analysed by one-way ANOVA and Tukey's post hoc test. N = 4, error bars are s.e.m.; *P < 0.05. Image collected and cropped by CiteAb from the following publication (//onlinelibrary.wiley.com/doi/10.15252/embr.201541726), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FUS-Antibody-Western-Blot-NB100-565-img0023.jpg)
![Immunocytochemistry/Immunofluorescence: FUS Antibody [NB100-565] - FUS (NB100-565) (green), b-III Tubulin (white), DAPI (blue). FUS antibody dilution: 1:300 in PBST (0.1% Triton X-100) + 10% GS O/N 4C. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/FUS-Antibody-Immunocytochemistry-Immunofluorescence-NB100-565-img0022.jpg)
![Immunohistochemistry-Paraffin: FUS Antibody [NB100-565] - FFPE section of mouse renal cells carcinoma. Affinity purified rabbit anti-FUS used at a dilution of 1:1,000 (1 ug/mL). Detection: DA](http://images.novusbio.com/fullsize/FUS-Antibody-Immunohistochemistry-Paraffin-NB100-565-img0017.jpg)
![Western Blot: FUS Antibody [NB100-565] - Whole cell lysate (50 ug) from HepG2, HeLa, 293T, and mouse NIH3T3 cells prepared using NETN lysis buffer. Affinity purified rabbit anti-FUS antibody used for WB at 0.04 ug/mL. Detection: chemiluminescence with an exposure time of 10 seconds.](http://images.novusbio.com/fullsize/FUS-Antibody-Western-Blot-NB100-565-img0019.jpg)
![Immunohistochemistry-Paraffin: FUS Antibody [NB100-565] - FFPE section of human ovarian carcinoma. Affinity purified rabbit anti-FUS used at a dilution of 1:1,000 (1 ug/mL). Detection: DAB](http://images.novusbio.com/fullsize/FUS-Antibody-Immunohistochemistry-Paraffin-NB100-565-img0015.jpg)
![<b>Independent Antibodies Validation. </b>Immunoprecipitation: FUS Antibody [NB100-565] - Detection of human FUS by Western blot of immunoprecipitates. Samples: Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HEK293T cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-FUS antibody NB100-565 used for IP at 3 ug per reaction. FUS was also immunoprecipitated by rabbit anti-FUS recombinant monoclonal antibody [BLR023E] (NBP2-76415) and rabbit anti-FUS antibody NB100-561. For blotting immunoprecipitated FUS, NB100-565 was used at 1:1000. Detection: Chemiluminescence with an exposure time time of 3 minutes.](http://images.novusbio.com/fullsize/FUS-Antibody-Immunoprecipitation-NB100-565-img0021.jpg)
![Immunocytochemistry/ Immunofluorescence: FUS Antibody [NB100-565] - hnRNP R & hnRNP Q form frequent inclusions in FTLD-FUS. Representative images of FUS, TRN1, hnRNP R & hnRNP Q immunohistochemical staining in the granule cell layer of the dentate fascia of the hippocampus in NIFID & aFTLD-U subtypes of FTLD-FUS. Single arrows indicate neuronal cytoplasmic inclusions & double arrows highlight intranuclear inclusions. Scale bars represent 50 μm in all images Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30755280), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-565_rabbit-polyclonal-fus-antibody-31020241517520.jpg)
![Immunocytochemistry/ Immunofluorescence: FUS Antibody [NB100-565] - hnRNP R co-localises with FUS inclusions in NIFID & aFTLD-U cases. Representative images of double-label immunofluorescence in the cortex (a & b) & granular cell layer of the dentate gyrus (c & d) of a NIFID & aFTLD-U case demonstrating colocalisation of FUS (green) & hnRNP R (red) in neuronal cytoplasmic inclusions (white arrows) & intranuclear neuronal inclusions (white arrow heads). Neuronal nuclei are counterstained with DAPI. Scale bars represent 20 μm in all images Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30755280), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-565_rabbit-polyclonal-fus-antibody-310202415291990.jpg)
![Western Blot: FUS Antibody [NB100-565] - Expression of EGFP‐FUS reduces the expression of endogenous FUSHEK293 cells were transfected with control EGFP, EGFP‐FUS, EGFP‐FUSR521C or EGFP‐FUSR518K & 72 h post‐transfection, the samples were probed on immunoblots for FUS (using FUS antibody) & tubulin as a loading control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27418313), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-565_rabbit-polyclonal-fus-antibody-31020241539718.jpg)
![Western Blot: FUS Antibody [NB100-565] - FUS does not bind VAPB or PTPIP51 in immunoprecipitation assays from transfected HEK293 cellsCells were transfected as indicated with control vector (CTRL), HA‐FUS + CTRL, myc‐VAPB + CTRL, or myc‐VAPB + either HA‐FUS, HA‐FUSR521C or HA‐FUSR518K. VAPB was immunoprecipitated via the myc‐tag & the samples probed on immunoblots for VAPB using rabbit VAPB antibody & for co‐immunoprecipitating FUS via the HA tag. Input VAPB & FUS were detected using myc & HA antibodies.Cells were transfected as indicated with control vector (CTRL), HA‐FUS + CTRL, HA‐PTPIP51 + CTRL or HA‐PTPIP51 + either HA‐FUS, HA‐FUSR521C or HA‐FUSR518K. PTPIP51 was immunoprecipitated using rat anti‐PTPIP51 & the samples probed for PTPIP51 using rabbit anti‐HA antibody & for co‐immunoprecipitating FUS using rabbit FUS antibody. Input PTPIP51 & FUS were detected using PTPIP51 & EGFP antibodies, respectively. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27418313), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-565_rabbit-polyclonal-fus-antibody-31020241552395.jpg)
![Western Blot: FUS Antibody [NB100-565] - FUS does not bind VAPB or PTPIP51 in immunoprecipitation assays from transfected HEK293 cellsCells were transfected as indicated with control vector (CTRL), HA‐FUS + CTRL, myc‐VAPB + CTRL, or myc‐VAPB + either HA‐FUS, HA‐FUSR521C or HA‐FUSR518K. VAPB was immunoprecipitated via the myc‐tag & the samples probed on immunoblots for VAPB using rabbit VAPB antibody & for co‐immunoprecipitating FUS via the HA tag. Input VAPB & FUS were detected using myc & HA antibodies.Cells were transfected as indicated with control vector (CTRL), HA‐FUS + CTRL, HA‐PTPIP51 + CTRL or HA‐PTPIP51 + either HA‐FUS, HA‐FUSR521C or HA‐FUSR518K. PTPIP51 was immunoprecipitated using rat anti‐PTPIP51 & the samples probed for PTPIP51 using rabbit anti‐HA antibody & for co‐immunoprecipitating FUS using rabbit FUS antibody. Input PTPIP51 & FUS were detected using PTPIP51 & EGFP antibodies, respectively. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27418313), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-565_rabbit-polyclonal-fus-antibody-31020241612640.jpg)
![Western Blot: FUS Antibody [NB100-565] - FUS does not bind VAPB or PTPIP51 in immunoprecipitation assays from transfected HEK293 cellsCells were transfected as indicated with control vector (CTRL), HA‐FUS + CTRL, myc‐VAPB + CTRL, or myc‐VAPB + either HA‐FUS, HA‐FUSR521C or HA‐FUSR518K. VAPB was immunoprecipitated via the myc‐tag & the samples probed on immunoblots for VAPB using rabbit VAPB antibody & for co‐immunoprecipitating FUS via the HA tag. Input VAPB & FUS were detected using myc & HA antibodies.Cells were transfected as indicated with control vector (CTRL), HA‐FUS + CTRL, HA‐PTPIP51 + CTRL or HA‐PTPIP51 + either HA‐FUS, HA‐FUSR521C or HA‐FUSR518K. PTPIP51 was immunoprecipitated using rat anti‐PTPIP51 & the samples probed for PTPIP51 using rabbit anti‐HA antibody & for co‐immunoprecipitating FUS using rabbit FUS antibody. Input PTPIP51 & FUS were detected using PTPIP51 & EGFP antibodies, respectively. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27418313), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-565_rabbit-polyclonal-fus-antibody-3102024168398.jpg)
![Western Blot: FUS Antibody [NB100-565] - Expression of wild‐type & ALS/FTD‐mutant FUS reduces ER–mitochondria associations in NSC34 cellsAExpression of FUS does not alter expression of VAPB, PTPIP51 or mitofusin‐2 (MFN2) in transfected NSC34 cells. Immunoblots of NSC34 cells transfected with EGFP as a control (CTRL), or wild‐type or mutant EGFP‐FUS. Transfected cells were purified via EGFP using a cell sorter & the samples probed on immunoblots as indicated. On the FUS immunoblot, samples were probed with FUS antibody to show endogenous & transfected proteins; tubulin is shown as a loading control.BRepresentative electron micrographs of ER–mitochondria associations in NSC34 cells transfected with control EGFP vector (CTRL), EGFP‐FUS, EGFP‐FUSR521C or EGFP‐FUSR518K as indicated; arrowheads with loops show regions of association. Scale bar = 200 nm. Bar chart shows % of the mitochondrial surface closely apposed to ER in the different samples. Data were analysed by one‐way analysis of variance (ANOVA) followed by Tukey's multiple comparison test. N = 27–30 cells & 247–424 mitochondria, error bars are s.e.m.; ***P < 0.001.C, DsiRNA loss of FUS does not affect ER–mitochondria associations or alter expression of VAPB, PTPIP51 or mitofusin‐2 (MFN2) in NSC34 cells. (C) Immunoblots of cells either mock transfected or treated with control (CTRL) or FUS siRNAs; GAPDH is shown as a loading control. (D) Representative electron micrographs of ER–mitochondria associations in control (CTRL) & FUS siRNA‐treated cells. Arrowheads with loops show regions of association. Scale bar = 200 nm. Data analysed by unpaired t‐test. N = 27–28 cells & 193–202 mitochondria, error bars are s.e.m. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27418313), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-565_rabbit-polyclonal-fus-antibody-31020241682165.jpg)
![Western Blot: alpha-Internexin Antibody (2E3) [NB300-140] - Analysis of different tissue lysates using alpha-Internexin, dilution 1:10000 (Red): [1] protein standard, [2] rat brain, [3] rat spinal cord, [4] mouse brain, [5] mouse spinal cord, and [6] cow spinal cord lysate. The antibody reveals the alpha-Internexin protein with an apparent molecular weight of 64-66kDa, with some variability across species.](http://images.novusbio.com/fullsize/alpha-Internexin-Antibody-2E3-Western-Blot-NB300-140-img0005.jpg "Western Blot: alpha-Internexin Antibody (2E3) [NB300-140] - Analysis of different tissue lysates using alpha-Internexin, dilution 1:10000 (Red): [1] protein standard, [2] rat brain, [3] rat spinal cord, [4] mouse brain, [5] mouse spinal cord, and [6] cow spinal cord lysate. The antibody reveals the alpha-Internexin protein with an apparent molecular weight of 64-66kDa, with some variability across species.")
![Immunocytochemistry/Immunofluorescence: alpha-Internexin Antibody (2E3) [NB300-140] - Hippocampal neurons in tissue culture with neurofilament alpha internexin (red), using NB300-140 and GFAP (green), using NB300-141.](http://images.novusbio.com/fullsize/alpha-Internexin-Antibody-2E3-Immunocytochemistry-Immunofluorescence-NB300-140-img0003.jpg)
![Immunohistochemistry: alpha-Internexin Antibody (2E3) [NB300-140] - Section of rat facial nucleus 7 days following axotomy. These neurons are capable of regenerating their axons and also, concomitant with regeneration, strongly upregulate alpha-Internexin in their perikarya. Other central neurons which are not able to regenerate their axons do not upregulate this protein after axotomy and untreated facial neurons normally show only very low levels of alpha-Internexin. Both findings suggest that alpha-Internexin has a role in axonal regeneration.](http://images.novusbio.com/fullsize/alpha-Internexin-Antibody-2E3-Immunohistochemistry-NB300-140-img0006.jpg)
![Simple Western: alpha-Internexin Antibody (2E3) [NB300-140] - Simple Western lane view shows a specific band for alpha Internexin in 0.5 mg/ml of SH-SY5Y lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/alpha-Internexin-Antibody-2E3-Simple-Western-NB300-140-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: CRBN Antibody [NBP1-91810] - Staining of human cell line U-251 MG shows localization to nucleoli. Antibody staining is shown in green.](http://images.novusbio.com/fullsize/CRBN-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-91810-img0027.jpg "Immunocytochemistry/Immunofluorescence: CRBN Antibody [NBP1-91810] - Staining of human cell line U-251 MG shows localization to nucleoli. Antibody staining is shown in green.")
![Western Blot: CRBN Antibody [NBP1-91810] - Analysis in mouse cell line NIH-3T3 and rat cell line NBT-II.](http://images.novusbio.com/fullsize/CRBN-Antibody-Western-Blot-NBP1-91810-img0025.jpg)
![Simple Western: CRBN Antibody [NBP1-91810] - Simple Western lane view shows a specific band for CRBN in 0.2 mg/ml of RT4 (left), U-251MG (right) lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/CRBN-Antibody-Simple-Western-NBP1-91810-img0014.jpg)
![Simple Western: CRBN Antibody [NBP1-91810] - Electropherogram image(s) of corresponding Simple Western lane view. CRBN antibody was used at 1:60 dilution on RT4 and U-251MG lysate(s).](http://images.novusbio.com/fullsize/CRBN-Antibody-Simple-Western-NBP1-91810-img0015.jpg)
![<b>Genetic Strategies Validation. </b>Single Cell Western: CRBN Antibody [NBP1-91810] - CRBN expression after Downregulation by siRNA, dilution 1:500. Single Cell Western Image submitted by verified customer review.](http://images.novusbio.com/fullsize/CRBN-Antibody-Single-Cell-Western-NBP1-91810-img0035.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: CRBN Antibody [NBP1-91810] - Validation of SALL4 asa bona fide IMiD-dependent CRL4CRBN substrate. Parental Kelly cells or two independent pools of CRBN -/- Kelly cells were treated with increasing concentrations of thalidomide. Following 24 h incubation, SALL4, CRBN, and GAPDH protein levels were assessed by western blot analysis. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30067223/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CRBN-Antibody-Western-Blot-NBP1-91810-img0036.jpg)
![Western Blot: NMDAR1 Antibody (R1JHL) [NB300-118] - 10 ug of rat hippocampal lysate showing specific immunolabeling of the ~120 kDa NR1 subunit of the NMDA receptor.](http://images.novusbio.com/fullsize/NMDAR1-Antibody-R1JHL-Western-Blot-NB300-118-img0001.jpg "Western Blot: NMDAR1 Antibody (R1JHL) [NB300-118] - 10 ug of rat hippocampal lysate showing specific immunolabeling of the ~120 kDa NR1 subunit of the NMDA receptor.")
![Western Blot: NMDAR1 Antibody (R1JHL) [NB300-118] - The blots show the examples of immunobands against NMDAR1 and beta-actin antibodies on the membrane, which was performed on the membrane protein prepared from the lumbar spinal cords of the offspring (P14) rats in different groups. Image collected and cropped by CiteAb from the following publication (//www.jbiomedsci.com/content/18/1/64) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NMDAR1-Antibody-R1JHL-Western-Blot-NB300-118-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: NMDAR1 Antibody (R1JHL) [NB300-118] - NR1 surface staining of mouse corical neruons. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/NMDAR1-Antibody-R1JHL-Immunocytochemistry-Immunofluorescence-NB300-118-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: NMDAR1 Antibody (R1JHL) [NB300-118] - Mouse neuron stained with anti-NMDAR1 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/NMDAR1-Antibody-R1JHL-Immunocytochemistry-Immunofluorescence-NB300-118-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: NMDAR1 Antibody (R1JHL) [NB300-118] - Mixed rat cortical cultures (21 DIV) were labelled with anti-NMDAR1 (1:200) and anti-mouse CF568 (1:250). The antibody labels small punctae along the neuronal processes. No distinct features such as spines are visible. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/NMDAR1-Antibody-R1JHL-Immunocytochemistry-Immunofluorescence-NB300-118-img0004.jpg)
![Immunocytochemistry/ Immunofluorescence: NMDAR1 Antibody (R1JHL) - Azide and BSA Free [NB300-118] - Notch1 colocalizes postsynaptically with Reelin signaling components. (A) Representative IEM images from hippocampal slices using an antibody specific for Notch1 show that gold particles are localized at postsynaptic as well as presynaptic membrane terminals. (B) Bar graph summarizing the counting of gold particles on the length of presynaptic & postsynaptic membranes indicates that the majority of the Notch1 gold particles are localized postsynaptically (5*10−3 ± 0.8*10−3 vs. 2*10−3 ± 0.4*10−3, n = 3 mice; Student’s t-test, p < 0.01). (C) Fluorescent immunolabeling on 14 days primary neuronal WT cultures shows colocalization of Notch1 & ApoER2 in soma & processes of pyramidal neurons. Both Notch1 & ApoER2 are similarly co-expressed in NMDAR1 positive puncta (R = 0.92 ± 0.03 & R = 0.86 ± 0.08, respectively; Student’s t-test, p = 0.23). (C′) Close up of a dendrite displaying Notch1, ApoER2 & NMDAR1 expression & “zoom in” captions of puncta showing clustering of the three receptors in teal. (D) Fluorescent immunolabeling on primary neuronal cultures shows that Notch1 & Dab1 localize in the same pyramidal neuron’s soma & processes labeled by phalloidin (R = 0.87 ± 0.06 & R = 0.74 ± 0.07 respectively; Student’s t-test, p = 0.5). (D′) Close up of a dendrite with Notch1, Dab1 & F-actin labeling & “zoom in” captions of dendritic puncta showing clustering of Notch1, Dab1 & F-actin in teal. **p < 0.01. Error bars are SEM & scale bar in (A) is 200 nm for all IEM panels, in (C,D) 50 μm & in (C′,D′) 10 μm & 500 nm in zoom in captions. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26635527), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-118_mouse-monoclonal-nmdar1-antibody-r1jhl-imgenex-img-5000-31020241620518.jpg)